Stock Price, News, Quote and Profile of BELLUS Health Inc(TSX:BLU) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BELLUS Health Inc

TSX:BLU (6/29/2023, 6:00:00 PM)

19.48

-0.02 (-0.1%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap2.47B

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

Toronto Stock Exchange Stock Screener

Find more stocks on Toronto Stock Exchange

GICS Sector Stock Screener

Find competitors from the same sector on the Canadian

GICS Industry Stock Screener

Find competitors from the same industry on the Canadian

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the Canadian

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the Canadian

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the Canadian

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the Canadian

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the Canadian

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the Canadian

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the Canadian

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the Canadian

Company Profile

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. The company is headquartered in Laval, Quebec and currently employs 74 full-time employees. The company went IPO on 2000-06-22. The firm's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The firm has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The firm is focused on initiating Phase III program. The firm is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

Company Info

BELLUS Health Inc

275 Armand-Frappier Blvd

Laval QUEBEC H7V 4A7

P: 14506804500.0

CEO: Roberto Bellini

Employees: 74

Website: https://bellushealth.com/

BLU.CA News

10 months ago - BELLUS Health Inc.Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health

/CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a...